Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

13-Week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel trial of 2 different dose regimens of lumiracoxib (100 mg od [once daily] and 200 mg od initial dose for two weeks followed by 100 mg od) in patients with primary knee osteoarthritis, using celecoxib (200 mg od) as a comparator

Next Previous
X
Search
Trial Profile

13-Week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel trial of 2 different dose regimens of lumiracoxib (100 mg od [once daily] and 200 mg od initial dose for two weeks followed by 100 mg od) in patients with primary knee osteoarthritis, using celecoxib (200 mg od) as a comparator

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2006

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lumiracoxib (Primary) ; Celecoxib
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Therapeutic Use
  • Sponsors Novartis

    • Most Recent Events

    • 07 Nov 2006 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top